Prognostic Value of ctDNA Detection in Patients With Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Systematic Review and Meta-analysis
The Oncologist · 2023
DOI: 10.1093/oncolo/oyad151 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The Oncologist, 2023. Verfasst von Lele Chang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Rectal Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Wu Jieping Medical Foundation.
Abstract (Originalsprache)
Background
Circulating tumor DNA (ctDNA) is increasingly used as a biomarker for metastatic rectal cancer and has recently shown promising results in the early detection of recurrence risk.
Methods
We conducted a systematic review and meta-analysis to explore the prognostic value of ctDNA detection in LARC patients undergoing neoadjuvant chemoradiotherapy (nCRT). We systematically searched electronic databases for observational or interventional studies that included LARC patients undergoing nCRT. Study selection according to the PRISMA guidelines and quality assessment of the REMARK tool for biomarker studies. The primary endpoint was the impact of ctDNA detection at different time points (baseline, post-nCRT, post-surgery) on relapse-free survival (RFS) and overall survival (OS). The secondary endpoint was to study the association between ctDNA detection and pathological complete response(pCR) at different time points.
Results
After further review and analysis of the 625 articles initially retrieved, we finally included 10 eligible studies. We found no significant correlation between ctDNA detection at baseline and long-term survival outcomes or the probability of achieving a pCR. However, the presence of ctDNA at post-nCRT was associated with worse RFS (HR = 9.16, 95% CI, 5.48-15.32), worse OS (HR = 8.49, 95% CI, 2.20-32.72), and worse pCR results (OR = 0.40, 95%CI, 0.18-0.89). The correlation between the presence of ctDNA at post-surgery and worse RFS was more obvious (HR = 14.94; 95% CI, 7.48-9.83).
Conclusions
Our results suggest that ctDNA detection is a promising biomarker for the evaluation of response and prognosis in LARC patients undergoing nCRT, which merits further evaluation in the following prospective trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China.
- Department of Thoracic Radiotherapy, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China.
- Department of Endoscopic Room, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China.
ORCID-Profile: Lele Chang, Ji Tao
Förderung
- Wu Jieping Medical Foundation
Zitieren
APA
Chang, L., Zhang, X., He, L., Ma, Q., Fang, T., Jiang, C., Ma, Z., Li, Q., Wu, C., & Tao, J. (2023). Prognostic Value of ctDNA Detection in Patients With Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Systematic Review and Meta-analysis. The Oncologist. https://doi.org/10.1093/oncolo/oyad151
Vancouver
Chang L, Zhang X, He L, Ma Q, Fang T, Jiang C, et al. Prognostic Value of ctDNA Detection in Patients With Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Systematic Review and Meta-analysis. The Oncologist. 2023. doi:10.1093/oncolo/oyad151
BibTeX
@article{Chang2023,
author = {Chang, Lele and Zhang, Xuemei and He, Lei and Ma, Qian and Fang, Tianyuan and Jiang, Chengzhi and Ma, Zhigang and Li, Qingwei and Wu, Chunlong and Tao, Ji},
title = {Prognostic Value of ctDNA Detection in Patients With Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Systematic Review and Meta-analysis},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyad151}
}
EUVIMED